Daniel K. Turner III is Director at Orexigen Therapeutics, Inc. (OREX). They have made 11 open-market trades across 3 companies since 2008, most recently 2015-06-24.
CIK 0001280249
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.1M since 2008, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OREX | BUY | 2011-12-22 | 2012-02-06 | $1.45 | $41K | N/A | N/A | N/A |
| TSPT | SELL | 2011-03-29 | 2011-03-30 | $8.17 | $531K | N/A | N/A | N/A |
| OREX | SELL | 2010-12-22 | 2010-12-23 | $8.25 | $429K | N/A | N/A | N/A |
| SOMX | SELL | 2010-03-18 | 2010-03-22 | $6.38 | $9.6M | N/A | N/A | N/A |
| OREX | SELL | 2009-12-17 | 2009-12-17 | $7.55 | $755K | N/A | N/A | N/A |
| OREX | SELL | 2009-09-22 | 2009-09-23 | $10.22 | $1.0M | N/A | N/A | N/A |
| OREX | SELL | 2009-09-17 | 2009-09-18 | $9.28 | $928K | N/A | N/A | N/A |
| OREX | SELL | 2009-09-14 | 2009-09-16 | $8.96 | $1.8M | N/A | N/A | N/A |
| TSPT | SELL | 2009-09-11 | 2009-09-14 | $12.59 | $75K | N/A | N/A | N/A |
| TSPT | SELL | 2009-09-09 | 2009-09-11 | $13.07 | $858K | N/A | N/A | N/A |
| OREX | BUY | 2008-12-05 | 2008-12-05 | $3.46 | $1.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.